Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Empagliflozin
95
CHF
CHF 95.00
In stock
AG-CR1-3619-M01010 mgCHF 95.00
AG-CR1-3619-M05050 mgCHF 250.00
| Product Details | |
|---|---|
| Synonyms | Jardiance; BI-10773; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol |
| Product Type | Chemical |
| Properties | |
| Formula |
C23H27ClO7 |
| MW | 450.9 |
| CAS | 864070-44-0 |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White solid. |
| Solubility | Soluble in DMSO. Slightly soluble in water or ethanol. |
| Identity | Determined by 1H-NMR. |
| InChi Key | OBWASQILIWPZMG-QZMOQZSNSA-N |
| Smiles | OCC1O[C@H](C(O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 3 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Antidiabetic agent.
- Potent and selective sodium glucose co-transporter 2 (SGLT-2) inhibitor. >300-fold selectivity over SGLT-1, 4, 5 and 6.
- SGLT-2 is found almost exclusively in the proximal tubules of nephronic components in kidneys. Inhibition of SGLT-2 reduces blood glucose by blocking renal glucose reabsorption and thereby increasing urinary glucose excretion (UGE).
- Shown to preserves β cell mass and restore glucose homeostasis.
Product References
- BI-10773, a sodium-glucose cotransporter 2 inhibitor for the potential oral treatment of type 2 diabetes mellitus: I. Aires & J. Calado; Curr. Opin. Investig. Drugs 11, 1182 (2010)
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors: R. Grempler, et al.; Diabetes Obes. Metab. 14, 83 (2012)
- Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats: L. Thomas, et al.; Diabetes Obes. Metab. 14, 94 (2012)
- Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. L. Seman, et al.; Clin. Pharmacol. Drug Dev. 2, 152 (2013)
- The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review: J.B. McGill; Diabetes Ther. 5, 43 (2014) (Review)
- Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes: E.M. Lamos, et al.; Expert Opin. Investig. Drugs 23, 875 (2014) (Review)
- The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat: H.H. Hansen, et al.; J. Pharmacol. Exp. Ther. 350, 657 (2014)
- Empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: A randomized, double-blind, placebo-controlled, phase 2 trial: S. Kullmann, et al.; Diabetes Care (Epub ahead of print) (2021)
- Gliflozins Have an Anti-Inflammatory Effect on Renal Proximal Tubular Epithelial Cells in a Diabetic and Inflammatory Microenvironment In Vitro: B. Koch, et al.; Int. J. Mol. Sci. 24, 1811 (2023)
Related Products
